Truist analyst Robyn Karnauskas reiterates a Buy rating on Absci and reinstated the firm’s $9 price target following the recent cash raise. The raise removes a key near-term overhang and extends Absci’s cash runway until 2027, the analyst tells investors in a research note. The firm sees Absci as a pure-play artificial intelligence tech enabled biotech company that is “making rapid strides in making in-silico based drug design and development a real possibility.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABSI:
- Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Cathie Wood’s ARK Investment bought 2.99M shares of Absci today
- Absci 16.7M share Spot Secondary priced at $4.50
- Absci Announces Pricing of Public Offering of Common Stock
- Absci Announces Proposed Public Offering of Common Stock